L. Zhang
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Pharmaceutical studies and practices, Asthma and respiratory diseases, Dermatology and Skin Diseases, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)(2017)92 cited
- → Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of UNCOVER‐3(2016)82 cited
- → The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate‐to‐severe plaque psoriasis(2017)42 cited
- → Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study(2019)29 cited
- → Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations(2017)14 cited
- → Pharmacokinetic evaluation of combined duloxetine and fluvoxamine dosing in CYP2D6 poor metabolizers(2005)7 cited
- → 398 Efficacy and safety of ixekizumab for the treatment of plaque psoriasis: Results through 108 weeks randomised, phase III clinical trial (UNCOVER-3)(2017)5 cited
- → An indirect comparison of long‐term efficacy of every‐2‐week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12(2019)3 cited
- → QT interval analyses from a placebo and positive controlled study evaluating the electrophysiological effects of duloxetine at supratherapeutic doses(2005)2 cited
- → PS02.18 Characterization of Patients with KRAS-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Community Practice Setting(2017)1 cited